Latest News and Press Releases

Phase 2/3 of the DRAGON II trial will evaluate the efficacy, safety, and tolerability of Tinlarebant in approximately 60 adolescent STGD1 subjects across the U.S., U.K., and JapanPhase 1b of DRAGON II...

在眼科領域，Scholl 博士是全球公認的領軍人物，同時也在史上規模最大的斯特格病變自然病史研究中擔任協調首席研究員 聖地牙哥, Sept. 04, 2024 (GLOBE NEWSWIRE) --  Belite Bio, Inc (NASDAQ: BLTE)（以下簡稱「Belite Bio」或「公司」）Belite Bio...

Scholl 博士是全球眼科领域备受推崇的领军人物，并在规模最大的斯特格病自然病程研究中担任协调首席研究员 圣迭戈, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc（纳斯达克股票代码：BLTE）（以下简称“Belite...

ショル博士は眼科の分野で世界的に認められたリーダーであり、スターガルト病の史上最大規模の自然史研究の調整主任研究者 サンディエゴ発, Sept. 04, 2024 (GLOBE NEWSWIRE) -- アンメット・メディカル・ニーズの変性網膜疾患を対象とした新規治療薬の開発に注力する臨床段階のバイオ医薬品開発会社であるベライト・バイオ (Belite Bio, Inc) (NASDAQ:...

SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...

Dr. Scholl adalah pemimpin yang diiktiraf di peringkat global dalam bidang oftalmologi dan penyelidik utama penyelaras bagi kajian sejarah semula jadi terbesar bagi penyakit Stargardt. SAN DIEGO,,...

안과 분야에서 세계적으로 인정받는 권위자인 Scholl 박사는 스타가르트 질환 관련 사상 최대 규모의 자연사 연구 공동 책임 연구자로도 활동 중 샌디에고, Sept. 02, 2024 (GLOBE NEWSWIRE) -- 임상 단계 바이오 의약품 개발 기업인 벨라이트 바이오(Belite Bio, Inc)(나스닥: BLTE)(이하 '벨라이트 바이오'...

Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural history study of Stargardt disease SAN DIEGO, Sept. ...

Tinlarebant, a novel oral therapy, is intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular...

SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...